Novira Therapeutics has expanded its series A round of financing to $25m after an investment of $7.5m from venture capital firm Versant Ventures.
US-based Novira Therapeutics, a US-based drug company treating infections backed by China’s WuXi PharmaTech, has extended to $25m its series A round after raising $7.5m from venture capital firm Versant Ventures.
Alongside WuXi PharmaTech, the round previously saw involvement from VC firms 5AM Ventures, Canaan Partners, BioAdvance, Mid-Atlantic Angel Group, Robin Hood Ventures and Delaware Crossing Investment Group.
Gianni Gromo, venture partner with Versant Ventures, will now join the company’s board of directors.
